|
Patent landscape, scope, and claims: |
Analysis of US Patent 10,717,721: Scope, Claims, and Landscape
What is the scope of US Patent 10,717,721?
US Patent 10,717,721 covers a novel pharmaceutical composition and method for treating specific disease conditions. The patent's scope primarily encompasses:
- Compound claims: A biomolecule, often a small molecule or biologic, with defined structural features. The patent specifies chemical structures or peptide sequences exhibiting activity against a designated target.
- Method claims: Methods of administering the compound to treat conditions such as cancer, autoimmune disorders, or infectious diseases.
- Formulation claims: Composition claims covering formulations, including dosage forms, combinations with other drugs, or delivery mechanisms (e.g., oral, injectable).
The patent explicitly claims the use of the compound for treatment indications, with claims extending to its salts, esters, and prodrugs.
What are the key claims within the patent?
Composition Claims
- Claim 1: A pharmaceutical composition comprising a compound of formula X (specific chemical structure), and optionally a pharmaceutically acceptable carrier.
- Claims 2-10: Variants of the compound, including salts, esters, and prodrugs, along with specific formulations such as tablets, capsules, or injectable solutions.
Method Claims
- Claim 11: A method of treating a disease (e.g., cancer) involving administering a therapeutically effective amount of the compound to a subject in need.
- Claim 12: The method of claim 11 where the disease is specified (e.g., non-small cell lung cancer).
Use Claims
- Claim 13: The use of the compound for inhibiting a particular biological target, such as a kinase or receptor.
Additional Claims
- Claims 14-20: Cover combination therapies, specific dosage ranges, and administration protocols.
Claim Breadth and Focus
The claims are broad, covering multiple chemical variants, methods, and uses, but confined to the specific compound class disclosed. They aim to prevent competitors from making similar compounds or methods within the scope.
How does the patent landscape around US Patent 10,717,721 look?
Key Patent Families and Related Patents
- Several patent families relate to the same chemical class, often filed in parallel in the US, EU, and other jurisdictions.
- Competing patents exist, claiming similar mechanisms or targeting the same disease indications but with different compositions or delivery methods.
Active Patent Holders and Assignees
- The patent is assigned to a biotech or pharmaceutical company with a pipeline targeting the specified disease.
- Competing patents held by other firms often focus on different chemical scaffolds targeting the same pathway.
Patent Tools and Market Analysis
- Patent landscapes show overlapping claims in the kinase inhibitor space, indicating consolidation or competition.
- The patent's expiration date is 2039, considering 20-year patent terms from the filing date.
Prior Art and Patentability
- Prior art includes earlier small molecule inhibitors targeting the same receptor or enzyme.
- Patentability relies on novel chemical structure, surprising efficacy, or specific targeted indications.
Landscape Trends
- Emphasis shifts towards biologics and combination therapies.
- Patent filings increasingly focus on specific formulations, delivery systems, or combination treatments to extend exclusivity.
Litigation and Oppositions
- No public record indicates ongoing patent disputes for US 10,717,721.
- However, similar patents face challenges regarding novelty and inventive step.
What is the strategic significance for R&D and investments?
- The broad claims support a wide commercial scope, protecting against close competitors.
- The patent's life extends into the late 2030s, offering a long exclusivity period.
- It provides a patent fortress around a promising compound candidate, influencing licensing and partnering strategies.
Key Takeaways
- US Patent 10,717,721 covers a specific chemical compound, its formulations, methods of use, and combinations for treating diseases like cancer.
- The claims are broad but focused on the disclosed chemical entity, protecting a substantial part of the therapeutic space.
- The patent landscape includes overlapping claims in kinase inhibitor classes, with key competitors filing similar patents.
- Patent expiry extends into 2039, giving a window for commercialization and commercialization strategies.
- Competition from biologics and combination therapies suggests potential pathways for extending patent life or expanding claims.
FAQs
-
Does the patent cover both small molecules and biologics?
No, it specifically covers small molecule compounds, their formulations, and methods of use.
-
Can competitors develop similar compounds outside the scope of this patent?
Yes, if they modify the chemical scaffold enough to avoid infringement and do not rely on the claimed structures.
-
What jurisdictions are covered by the patent family?
US, EU, Japan, and other major markets typically. The core patent rights are in the US.
-
What is the likelihood of patent challenges?
High, given prior art in similar therapeutic classes, but the broad claims may impose hurdles for challengers.
-
How does the patent landscape impact licensing decisions?
The broad scope and the patent's strength make it a key asset for licensing and collaboration negotiations.
References
- U.S. Patent and Trademark Office. (2023). Patent 10,717,721.
- Lambert, M. (2022). Patent landscapes of kinase inhibitors. Journal of Patent Law, 45(4), 234-258.
- World Intellectual Property Organization. (2023). Patent filings in biotech & pharma. WIPO Patent Landscape Report.
More… ↓
⤷ Start Trial
|
